IRIDEX Announces Preliminary Revenues for 2016 Third Quarter Mountain View, CA.

IRIDEX Announces Preliminary Revenues for 2016 Third Quarter

Mountain View, CA. October 11, 2016 IRIDEX Corporation (Nasdaq: IRIX) today reported preliminary revenues of

approximately $9.6 to $9.7 million for the third quarter ended October 1, 2016 compared to prior revenue guidance of $11.0 to $11.3 million. While demand for the Company s new flagship Cyclo G6 laser platform for glaucoma remained

strong, revenues of certain retina products were below expectations although the Company ended the third quarter with a record high in back orders.

The Company expects to release its full results for the third quarter in early November 2016.

Recent Business Highlights

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile

laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is

dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of

70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.

Safe Harbor Statement

contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning its anticipated revenues for

the quarter ended October 1, 2016, demand for the G6 platform, FDA authorization for the G6 platform, the causes of back orders with certain retina products and the Company s expectations to resolve those issues and ship its back orders,

and the timing of the release of the Company s full financial results for 2016 third quarter. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking

statements as a result of a number of factors, including: accounting adjustments made by the Company in the process of closing the 2016 third quarter; the Company s ongoing evaluation of the causes of the issues experienced in the 2016 third

quarter; quality and control and production issues; defects in product design; risks associated with international sales; general economic and political conditions globally or regionally; business and economic conditions in the industries in which

the Company operates; the ability to develop new products; the ability of new and existing products to achieve and maintain market acceptance; increases in and effects of competition; uncertainty regarding healthcare reform measures and changes in

third-party coverage and reimbursement policies; changes in collaborative relationships; changes in unit pricing of products; changes in sales force or distributor relationships; any failure to manage growth in the Company s business, including

growth through acquisitions; any failure to maintain or successfully protect intellectual property rights; any loss of key personnel; any failure to accurately forecast demand for the Company s products; reliance on sole and limited source

suppliers; the impact of FDA, environmental and other regulations on business; any failure to comply with regulatory and legal requirements; loss of reputation, including as a result of any misuse of products; any recalls of products; and product

liability and other legal claims. Please see a detailed description of these and other risks contained in the Company s Annual Report on Form 10-K for the fiscal year ended January 2, 2016, and Quarterly Reports on Form 10-Q for subsequent

fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.